title: Influence of systemic chemotherapy on anti-P-glycoprotein antibody-dependent cell-mediated cytotoxicity in patients with small cell lung cancer.
abstract: Anti-P-glycoprotein antibody (MRK-16)-dependent cell-mediated cytotoxicity (ADCC) by blood mononuclear cells (MNC) was examined in patients with small cell lung cancer (SCLC) before and after systemic chemotherapy. The effect of in vitro treatment of MNC with interleukin (IL)-2 and macrophage-colony-stimulating factor (M-CSF) was also examined. The ADCC reaction was assessed by a 6 h 51Cr-release assay using a multidrug-resistant (MDR) SCLC cell line (H69/VP cells). The MRK-16 monoclonal antibody was able to augment spontaneous cytotoxicity by MNC, even in SCLC patients. Pretreatment of MNC with IL-2 significantly augmented their ADCC ability in SCLC patients, while M-CSF had no effect on ADCC activity. After the first cycle of systemic chemotherapy, the ADCC activity tended to decline, but ADCC of MNC pretreated with IL-2 was not affected. The results suggest that anti-P-glycoprotein antibody, in combination with a cytokine such as IL-2, may be therapeutically useful against human SCLC resistant to chemotherapeutic drugs.
authors.affiliation: Third Department of Internal Medicine, University of Tokushima School of Medicine.
authors.forename: R
authors.initials: R
authors.lastname: Nabioullin
authors.forename: H
authors.initials: H
authors.lastname: Yanagawa
authors.forename: T
authors.initials: T
authors.lastname: Haku
authors.forename: K
authors.initials: K
authors.lastname: Hiramatsu
authors.forename: S
authors.initials: S
authors.lastname: Yano
authors.forename: M
authors.initials: M
authors.lastname: Hanibuchi
authors.forename: K
authors.initials: K
authors.lastname: Pai
authors.forename: T
authors.initials: T
authors.lastname: Tsuruo
authors.forename: S
authors.initials: S
authors.lastname: Sone
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000276:immunology*; D000911:Antibodies, Monoclonal; D000920:Antibody-Dependent Cell Cytotoxicity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology* / Q000628:therapy; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D018432:Drug Resistance, Multiple; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000276:immunology* / Q000628:therapy; D016173:Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D005047:Etoposide; D004317:Doxorubicin; D016173:Macrophage Colony-Stimulating Factor; D016190:Carboplatin; D002945:Cisplatin